{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:04:55Z","timestamp":1790910295046,"version":"4.1.0"},"reference-count":174,"publisher":"Bentham Science Publishers Ltd.","issue":"32","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CTMC"],"published-print":{"date-parts":[[2020,12,3]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Cardiovascular diseases (CVDs) are the leading global cause of death, accounting for more\nthan 17.6 million deaths per year in 2016, a number that is expected to grow to more than 23.6 million\nby 2030. While many technologies are currently under investigation to improve the therapeutic outcome\nof CVD complications, only a few medications have been approved. Therefore, new approaches\nto treat CVD are urgently required. Peptides regulate numerous physiological processes, mainly by\nbinding to specific receptors and inducing a series of signals, neurotransmissions or the release of\ngrowth factors. Importantly, peptides have also been shown to play an important role in the circulatory\nsystem both in physiological and pathological conditions. Peptides, such as angiotensin II, endothelin,\nurotensin-II, urocortins, adrenomedullin and natriuretic peptides have been implicated in the control of\nvascular tone and blood pressure as well as in CVDs such as congestive heart failure, atherosclerosis,\ncoronary artery disease, and pulmonary and systemic hypertension. Hence it is not surprising that peptides\nare becoming important therapeutic leads in CVDs. This article will review the current knowledge\non peptides and their role in the circulatory system, focusing on the physiological roles of natriuretic\npeptides in the cardiovascular system and their implications in CVDs.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568026620666201013154326","type":"journal-article","created":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T06:21:03Z","timestamp":1602656463000},"page":"2904-2921","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Natriuretic Peptides as the Basis of Peptide Drug Discovery for Cardiovascular Diseases"],"prefix":"10.2174","volume":"20","author":[{"given":"Yana","family":"Lerner","sequence":"first","affiliation":[{"name":"The Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Henrietta Szold St. 8, P.O. Box 1589, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessal","family":"Hanout","sequence":"additional","affiliation":[{"name":"The Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Henrietta Szold St. 8, P.O. Box 1589, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulamit Fluss","family":"Ben-Uliel","sequence":"additional","affiliation":[{"name":"The Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Henrietta Szold St. 8, P.O. Box 1589, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samar","family":"Gani","sequence":"additional","affiliation":[{"name":"The Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Henrietta Szold St. 8, P.O. Box 1589, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal Pellach","family":"Leshem","sequence":"additional","affiliation":[{"name":"The Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Henrietta Szold St. 8, P.O. Box 1589, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Qvit","sequence":"additional","affiliation":[{"name":"The Azrieli Faculty of Medicine in the Galilee, Bar-Ilan University, Henrietta Szold St. 8, P.O. Box 1589, Safed, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S0140-6736(12)60916-7","volume":"381","author":"Heusch G.","year":"2013","unstructured":"Heusch G.; Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013,381(9861),166-175","journal-title":"Lancet"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","volume":"137","author":"Benjamin E.J.","year":"2018","unstructured":"Benjamin E.J.; Virani S.S.; Callaway C.W.; Chamberlain A.M.; Chang A.R.; Cheng S.; Chiuve S.E.; Cushman M.; Delling F.N.; Deo R.; de Ferranti S.D.; Ferguson J.F.; Fornage M.; Gillespie C.; Isasi C.R.; Jim\u00e9nez M.C.; Jordan L.C.; Judd S.E.; Lackland D.; Lichtman J.H.; Lisabeth L.; Liu S.; Longenecker C.T.; Lutsey P.L.; Mackey J.S.; Matchar D.B.; Matsushita K.; Mussolino M.E.; Nasir K.; O\u2019Flaherty M.; Palaniappan L.P.; Pandey A.; Pandey D.K.; Reeves M.J.; Ritchey M.D.; Rodriguez C.J.; Roth G.A.; Rosamond W.D.; Sampson U.K.A.; Satou G.M.; Shah S.H.; Spartano N.L.; Tirschwell D.L.; Tsao C.W.; Voeks J.H.; Willey J.Z.; Wilkins J.T.; Wu J.H.; Alger H.M.; Wong S.S.; Muntner P.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2018 update: A report from the american heart association. Circulation 2018,137(12),e67-e492","journal-title":"Circulation"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1161\/CIRCRESAHA.115.306825","volume":"118","author":"Bhupathiraju S.N.","year":"2016","unstructured":"Bhupathiraju S.N.; Hu F.B.; Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res 2016,118(11),1723-1735","journal-title":"Circ Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMra1606915","volume":"376","author":"Anderson J.L.","year":"2017","unstructured":"Anderson J.L.; Morrow D.A.; Acute myocardial infarction. N Engl J Med 2017,376(21),2053-2064","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.gheart.2018.09.511","volume":"13","author":"Thomas H.","year":"2018","unstructured":"Thomas H.; Diamond J.; Vieco A.; Chaudhuri S.; Shinnar E.; Cromer S.; Perel P.; Mensah G.A.; Narula J.; Johnson C.O.; Roth G.A.; Moran A.E.; Global atlas of cardiovascular disease 2000-2016: The path to prevention and control. Glob Heart 2018,13(3),143-163","journal-title":"Glob Heart"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drudis.2014.10.003","volume":"20","author":"Fosgerau K.","year":"2015","unstructured":"Fosgerau K.; Hoffmann T.; Peptide therapeutics: Current status and future directions. Drug Discov Today 2015,20(1),122-128","journal-title":"Drug Discov Today"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1021\/ja00897a025","volume":"85","author":"Merrifield R.B.","year":"1963","unstructured":"Merrifield R.B.; Solid phase peptide synthesis I. The synthesis of a tetrapeptide. J Am Chem Soc 1963,85,2149-2154","journal-title":"J Am Chem Soc"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nrd.2018.183","volume":"18","author":"Anselmo A.C.","year":"2019","unstructured":"Anselmo A.C.; Gokarn Y.; Mitragotri S.; Non-invasive delivery strategies for biologics. Nat Rev Drug Discov 2019,18(1),19-40","journal-title":"Nat Rev Drug Discov"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2533\/chimia.2013.899","volume":"67","author":"Marzinzik A.L.","year":"2013","unstructured":"Marzinzik A.L.; Vorherr T.E.; Towards intracellular delivery of peptides. Chimia (Aarau) 2013,67(12-13),899-904","journal-title":"Chimia (Aarau)"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.euprot.2014.05.003","volume":"4","author":"Uhlig T.","year":"2014","unstructured":"Uhlig T.; The emergence of peptides in the pharmaceutical business: from exploration to exploitation. EuPA Open Proteom 2014,4,58-69","journal-title":"EuPA Open Proteom"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.4155\/fmc.15.43","volume":"7","author":"Vorherr T.","year":"2015","unstructured":"Vorherr T.; Modifying peptides to enhance permeability. Future Med Chem 2015,7(8),1009-1021","journal-title":"Future Med Chem"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/B978-0-12-801028-0.00171-9","author":"Ogoshi M.","year":"2016","unstructured":"Ogoshi M.;  Handbook of hormones 2016,235-233","journal-title":"Handbook of hormones"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3389\/fphys.2019.00821","volume":"10","author":"Kumar A.","year":"2019","unstructured":"Kumar A.; Potts J.D.; DiPette D.J.; Protective role of alpha-calcitonin gene-related peptide in cardiovascular diseases. Front Physiol 2019,10,821","journal-title":"Front Physiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/B978-0-12-385095-9.00189-5","author":"King R.","year":"2013","unstructured":"King R.; Brain S.D.;  Handbook of biologically active peptides 2013,1394-1401","journal-title":"Handbook of biologically active peptides"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"Mehta P.K.","year":"2007","unstructured":"Mehta P.K.; Griendling K.K.; Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007,292(1),C82-C97","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.abb.2018.11.021","volume":"662","author":"Grieco P.","year":"2019","unstructured":"Grieco P.; Gomez-Monterrey I.; Natural and synthetic peptides in the cardiovascular diseases: An update on diagnostic and therapeutic potentials. Arch Biochem Biophys 2019,662,15-32","journal-title":"Arch Biochem Biophys"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/965140","volume":"2013","author":"Sato K.","year":"2013","unstructured":"Sato K.; Watanabe R.; Itoh F.; Shichiri M.; Watanabe T.; Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases. Int J Hypertens 2013,2013","journal-title":"Int J Hypertens"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.peptides.2010.12.012","volume":"32","author":"Suzuki N.","year":"2011","unstructured":"Suzuki N.; Shichiri M.; Tateno T.; Sato K.; Hirata Y.; Distinct systemic distribution of salusin-\u03b1 and salusin-\u03b2 in the rat. Peptides 2011,32(4),805-810","journal-title":"Peptides"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/nm913","volume":"9","author":"Shichiri M.","year":"2003","unstructured":"Shichiri M.; Ishimaru S.; Ota T.; Nishikawa T.; Isogai T.; Hirata Y.; Salusins: newly identified bioactive peptides with hemodynamic and mitogenic activities. Nat Med 2003,9(9),1166-1172","journal-title":"Nat Med"},{"key":"ref=20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076714","volume":"8","author":"Fujimoto K.","year":"2013","unstructured":"Fujimoto K.; Hayashi A.; Kamata Y.; Ogawa A.; Watanabe T.; Ichikawa R.; Iso Y.; Koba S.; Kobayashi Y.; Koyama T.; Shichiri M.; Circulating levels of human salusin-\u03b2, a potent hemodynamic and atherogenesis regulator. PLoS One 2013,8(10)","journal-title":"PLoS One"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00467-014-2960-y","volume":"30","author":"Ko\u0142akowska U.","year":"2015","unstructured":"Ko\u0142akowska U.; Kuroczycka-Saniutycz E.; Wasilewska A.; Ola\u0144ski W.; Is the serum level of salusin-\u03b2 associated with hypertension and atherosclerosis in the pediatric population? Pediatr Nephrol 2015,30(3),523-531","journal-title":"Pediatr Nephrol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.jash.2011.06.003","volume":"5","author":"Watanabe T.","year":"2011","unstructured":"Watanabe T.; Sato K.; Itoh F.; Iso Y.; Nagashima M.; Hirano T.; Shichiri M.; The roles of salusins in atherosclerosis and related cardiovascular diseases. J Am Soc Hypertens 2011,5(5),359-365","journal-title":"J Am Soc Hypertens"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/bcp.13033","volume":"82","author":"Stirrat C.G.","year":"2016","unstructured":"Stirrat C.G.; Venkatasubramanian S.; Pawade T.; Mitchell A.J.; Shah A.S.; Lang N.N.; Newby D.E.; Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. Br J Clin Pharmacol 2016,82(4),974-982","journal-title":"Br J Clin Pharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/187152710793361513","volume":"9","author":"Cong W.N.","year":"2010","unstructured":"Cong W.N.; Golden E.; Pantaleo N.; White C.M.; Maudsley S.; Martin B.; Ghrelin receptor signaling: a promising therapeutic target for metabolic syndrome and cognitive dysfunction. CNS Neurol Disord Drug Targets 2010,9(5),557-563","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/MCO.0b013e328365b9be","volume":"16","author":"Pradhan G.","year":"2013","unstructured":"Pradhan G.; Samson S.L.; Sun Y.; Ghrelin: much more than a hunger hormone. Curr Opin Clin Nutr Metab Care 2013,16(6),619-624","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"Holst J.J.","year":"2007","unstructured":"Holst J.J.; The physiology of glucagon-like peptide 1. Physiol Rev 2007,87(4),1409-1439","journal-title":"Physiol Rev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/CIRCHEARTFAILURE.108.810887","volume":"1","author":"Hausenloy D.J.","year":"2008","unstructured":"Hausenloy D.J.; Yellon D.M.; GLP-1 therapy: beyond glucose control. Circ Heart Fail 2008,1(3),147-149","journal-title":"Circ Heart Fail"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/eurheartj\/ehr309","volume":"33","author":"L\u00f8nborg J.","year":"2012","unstructured":"L\u00f8nborg J.; Vejlstrup N.; Kelb\u00e6k H.; B\u00f8tker H.E.; Kim W.Y.; Mathiasen A.B.; J\u00f8rgensen E.; Helqvist S.; Saunam\u00e4ki K.; Clemmensen P.; Holmvang L.; Thuesen L.; Krusell L.R.; Jensen J.S.; K\u00f8ber L.; Treiman M.; Holst J.J.; Engstr\u00f8m T.; Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012,33(12),1491-1499","journal-title":"Eur Heart J"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1161\/ATVBAHA.113.301586","volume":"33","author":"Woo J.S.","year":"2013","unstructured":"Woo J.S.; Kim W.; Ha S.J.; Kim J.B.; Kim S.J.; Kim W.S.; Seon H.J.; Kim K.S.; Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 2013,33(9),2252-2260","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","volume":"53","author":"Timmers L.","year":"2009","unstructured":"Timmers L.; Henriques J.P.; de Kleijn D.P.; Devries J.H.; Kemperman H.; Steendijk P.; Verlaan C.W.; Kerver M.; Piek J.J.; Doevendans P.A.; Pasterkamp G.; Hoefer I.E.; Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009,53(6),501-510","journal-title":"J Am Coll Cardiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/bph.12959","volume":"172","author":"Inserte J.","year":"2015","unstructured":"Inserte J.; Garcia-Dorado D.; The cGMP\/PKG pathway as a common mediator of cardioprotection: translatability and mechanism. Br J Pharmacol 2015,172(8),1996-2009","journal-title":"Br J Pharmacol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.ijcard.2016.06.283","volume":"220","author":"Roos S.T.","year":"2016","unstructured":"Roos S.T.; Timmers L.; Biesbroek P.S.; Nijveldt R.; Kamp O.; van Rossum A.C.; van Hout G.P.; Stella P.R.; Doevendans P.A.; Knaapen P.; Velthuis B.K.; van Royen N.; Voskuil M.; Nap A.; Appelman Y.; No benefit of additional treatment with exenatide in patients with an acute myocardial infarction. Int J Cardiol 2016,220,809-814","journal-title":"Int J Cardiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.hlc.2016.07.006","volume":"26","author":"Zheng A.","year":"2017","unstructured":"Zheng A.; Cao L.; Qin S.; Chen Y.; Li Y.; Zhang D.; Exenatide regulates substrate preferences through the p38\u03b3 MAPK pathway after ischaemia\/reperfusion injury in a rat heart. Heart Lung Circ 2017,26(4),404-412","journal-title":"Heart Lung Circ"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.hlc.2016.08.007","volume":"26","author":"Lee K.H.","year":"2017","unstructured":"Lee K.H.; Ha S.J.; Woo J.S.; Lee G.J.; Lee S.R.; Kim J.W.; Park H.K.; Kim W.; Exenatide prevents morphological and structural changes of mitochondria following ischaemia-reperfusion injury. Heart Lung Circ 2017,26(5),519-523","journal-title":"Heart Lung Circ"},{"key":"ref=35","first-page":"1693","volume":"41","author":"Chang G.","year":"2018","unstructured":"Chang G.; Liu J.; Qin S.; Jiang Y.; Zhang P.; Yu H.; Lu K.; Zhang N.; Cao L.; Wang Y.; Li Y.; Zhang D.; Cardioprotection by exenatide: A novel mechanism via improving mitochondrial function involving the GLP-1 receptor\/cAMP\/PKA pathway. Int J Mol Med 2018,41(3),1693-1703","journal-title":"Int J Mol Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"C270","DOI":"10.1152\/ajpcell.00194.2015","volume":"310","author":"Du J.","year":"2016","unstructured":"Du J.; Zhang L.; Wang Z.; Yano N.; Zhao Y.T.; Wei L.; Dubielecka-Szczerba P.; Liu P.Y.; Zhuang S.; Qin G.; Zhao T.C.; Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted hearts. Am J Physiol Cell Physiol 2016,310(4),C270-C283","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.peptides.2017.02.008","volume":"90","author":"Chen J.","year":"2017","unstructured":"Chen J.; Wang D.; Wang F.; Shi S.; Chen Y.; Yang B.; Tang Y.; Huang C.; Exendin-4 inhibits structural remodeling and improves Ca2+ homeostasis in rats with heart failure via the GLP-1 receptor through the eNOS\/cGMP\/PKG pathway. Peptides 2017,90,69-77","journal-title":"Peptides"},{"key":"ref=38","volume":"40","author":"Siraj M.A.","year":"2019","unstructured":"Siraj M.A.;  GLP-1(28-36) prevents progression of ischemic heart failure in mice. Eur. Heart J. 2019,40(Supplement_1)"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s12020-016-1166-4","volume":"57","author":"Arturi F.","year":"2017","unstructured":"Arturi F.; Succurro E.; Miceli S.; Cloro C.; Ruffo M.; Maio R.; Perticone M.; Sesti G.; Perticone F.; Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine 2017,57(3),464-473","journal-title":"Endocrine"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.2147\/DDDT.S213910","volume":"13","author":"Zheng R-H.","year":"2019","unstructured":"Zheng R-H.; Bai X.J.; Zhang W.W.; Wang J.; Bai F.; Yan C.P.; James E.A.; Bose H.S.; Wang N.P.; Zhao Z.Q.; Liraglutide attenuates cardiac remodeling and improves heart function after abdominal aortic constriction through blocking angiotensin II type 1 receptor in rats. Drug Des Devel Ther 2019,13,2745-2757","journal-title":"Drug Des Devel Ther"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"Marso S.P.","year":"2016","unstructured":"Marso S.P.; Daniels G.H.; Brown-Frandsen K.; Kristensen P.; Mann J.F.; Nauck M.A.; Nissen S.E.; Pocock S.; Poulter N.R.; Ravn L.S.; Steinberg W.M.; Stockner M.; Zinman B.; Bergenstal R.M.; Buse J.B.;  LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016,375(4),311-322","journal-title":"N Engl J Med"},{"key":"ref=42","volume":"40","author":"Steven S.","year":"2019","unstructured":"Steven S.; Cardiovascular benefits of GLP-1 (liraglutide) treatment in experimental arterial hypertension are mediated by the endothelial GLP-1 receptor. Eur. Heart J. 2019,40(Supplement. 1)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","volume":"40","author":"Helmst\u00e4dter J.","year":"2020","unstructured":"Helmst\u00e4dter J.; Frenis K.; Filippou K.; Grill A.; Dib M.; Kalinovic S.; Pawelke F.; Kus K.; Kr\u00f6ller-Sch\u00f6n S.; Oelze M.; Chlopicki S.; Schuppan D.; Wenzel P.; Ruf W.; Drucker D.J.; M\u00fcnzel T.; Daiber A.; Steven S.; Endothelial GLP-1 (Glucagon-like peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension. Arterioscler Thromb Vasc Biol 2020,40(1),145-158","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0008-6363(00)00229-7","volume":"49","author":"Henning R.J.","year":"2001","unstructured":"Henning R.J.; Sawmiller D.R.; Vasoactive intestinal peptide: cardiovascular effects. Cardiovasc Res 2001,49(1),27-37","journal-title":"Cardiovasc Res"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1172\/JCI17500","volume":"111","author":"Petkov V.","year":"2003","unstructured":"Petkov V.; Mosgoeller W.; Ziesche R.; Raderer M.; Stiebellehner L.; Vonbank K.; Funk G.C.; Hamilton G.; Novotny C.; Burian B.; Block L.H.; Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003,111(9),1339-1346","journal-title":"J Clin Invest"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11906-018-0811-0","volume":"20","author":"Lozi\u0107 M.","year":"2018","unstructured":"Lozi\u0107 M.; \u0160arenac O.; Murphy D.; Japund\u017ei\u0107-\u017digon N.; Vasopressin, central autonomic control and blood pressure regulation. Curr Hypertens Rep 2018,20(2),11","journal-title":"Curr Hypertens Rep"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.4081\/bam.2014.3.217","volume":"24","author":"Costa A.","year":"2014","unstructured":"Costa A.; Rossi E.; Scicchitano B.M.; Coletti D.; Moresi V.; Adamo S.; Neurohypophyseal hormones: novel actors of striated muscle development and homeostasis. Eur J Transl Myol 2014,24(3),3790","journal-title":"Eur J Transl Myol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-neuro-071714-033904","volume":"38","author":"Stoop R.","year":"2015","unstructured":"Stoop R.; Hegoburu C.; van den Burg E.; New opportunities in vasopressin and oxytocin research: a perspective from the amygdala. Annu Rev Neurosci 2015,38,369-388","journal-title":"Annu Rev Neurosci"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.4103\/2230-8210.84851","volume":"15","author":"Magon N.","year":"2011","unstructured":"Magon N.; Kalra S.; The orgasmic history of oxytocin: Love, lust, and labor. Indian J Endocrinol Metab 2011,15(Suppl. 3),S156-S161","journal-title":"Indian J Endocrinol Metab"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fnins.2019.00454","volume":"13","author":"Wang P.","year":"2019","unstructured":"Wang P.; Wang S.C.; Yang H.; Lv C.; Jia S.; Liu X.; Wang X.; Meng D.; Qin D.; Zhu H.; Wang Y.F.; Therapeutic potential of oxytocin in atheroscleroticc Cardiovascular disease: mechanisms and signaling pathways. Front Neurosci 2019,13,454","journal-title":"Front Neurosci"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1124\/pr.115.011833","volume":"68","author":"Davenport A.P.","year":"2016","unstructured":"Davenport A.P.; Hyndman K.A.; Dhaun N.; Southan C.; Kohan D.E.; Pollock J.S.; Pollock D.M.; Webb D.J.; Maguire J.J.; Endothelin. Pharmacol Rev 2016,68(2),357-418","journal-title":"Pharmacol Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1172\/JCI115915","volume":"90","author":"Firth J.D.","year":"1992","unstructured":"Firth J.D.; Ratcliffe P.J.; Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 1992,90(3),1023-1031","journal-title":"J Clin Invest"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/157489006775244263","volume":"1","author":"Hynynen M.M.","year":"2006","unstructured":"Hynynen M.M.; Khalil R.A.; The vascular endothelin system in hypertension--recent patents and discoveries. Recent Pat Cardiovasc Drug Discov 2006,1(1),95-108","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"4390","DOI":"10.3892\/ol.2017.6027","volume":"13","author":"Zhang Z.Y.","year":"2017","unstructured":"Zhang Z.Y.; Chen L.L.; Xu W.; Sigdel K.; Jiang X.T.; Effects of silencing endothelin-1 on invasion and vascular formation in lung cancer. Oncol Lett 2017,13(6),4390-4396","journal-title":"Oncol Lett"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.lfs.2008.01.008","volume":"82","author":"Zhang W-M.","year":"2008","unstructured":"Zhang W-M.; Zhou J.; Ye Q.J.; Endothelin-1 enhances proliferation of lung cancer cells by increasing intracellular free Ca2+. Life Sci 2008,82(13-14),764-771","journal-title":"Life Sci"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/B978-0-12-801028-0.00182-3","author":"Wong M.K.S.","year":"2016","unstructured":"Wong M.K.S.;  Handbook of Hormones 2016,274-274","journal-title":"Handbook of Hormones"},{"key":"ref=57","first-page":"124","volume":"11","author":"Golias Ch.","year":"2007","unstructured":"Golias Ch.; Charalabopoulos A.; Stagikas D.; Charalabopoulos K.; Batistatou A.; The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin. Hippokratia 2007,11(3),124-128","journal-title":"Hippokratia"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1515\/hsz-2015-0240","volume":"397","author":"Regoli D.","year":"2016","unstructured":"Regoli D.; Gobeil F.; Kinins and peptide receptors. Biol Chem 2016,397(4),297-304","journal-title":"Biol Chem"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ejheart.2008.06.002","volume":"10","author":"Chandrasekaran B.","year":"2008","unstructured":"Chandrasekaran B.; Dar O.; McDonagh T.; The role of apelin in cardiovascular function and heart failure. Eur J Heart Fail 2008,10(8),725-732","journal-title":"Eur J Heart Fail"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pharmthera.2005.04.001","volume":"107","author":"Kleinz M.J.","year":"2005","unstructured":"Kleinz M.J.; Davenport A.P.; Emerging roles of apelin in biology and medicine. Pharmacol Ther 2005,107(2),198-211","journal-title":"Pharmacol Ther"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/B978-1-4160-3053-9.50009-3","author":"Franco V.","year":"2007","unstructured":"Franco V.;  Hypertension (Dallas, Tex: 1979) 2007,25-46","journal-title":"Hypertension (Dallas, Tex: 1979)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/B978-1-4160-5895-3.10037-3","author":"Slavin L.","year":"2011","unstructured":"Slavin L.;  Heart Failure: A Companion to Braunwald\u2019s Heart Disease 2011,545-559","journal-title":"Heart Failure: A Companion to Braunwald\u2019s Heart Disease"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejphar.2015.06.061","volume":"764","author":"Kato J.","year":"2015","unstructured":"Kato J.; Kitamura K.; Bench-to-bedside pharmacology of adrenomedullin. Eur J Pharmacol 2015,764,140-148","journal-title":"Eur J Pharmacol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.toxicon.2010.12.001","volume":"59","author":"Vink S.","year":"2012","unstructured":"Vink S.; Jin A.H.; Poth K.J.; Head G.A.; Alewood P.F.; Natriuretic peptide drug leads from snake venom. Toxicon 2012,59(4),434-445","journal-title":"Toxicon"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd1197","volume":"2","author":"Lewis R.J.","year":"2003","unstructured":"Lewis R.J.; Garcia M.L.; Therapeutic potential of venom peptides. Nat Rev Drug Discov 2003,2(10),790-802","journal-title":"Nat Rev Drug Discov"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.toxicon.2011.07.013","volume":"59","author":"Camargo A.C.M.","year":"2012","unstructured":"Camargo A.C.M.; Ianzer D.; Guerreiro J.R.; Serrano S.M.; Bradykinin-potentiating peptides: beyond captopril. Toxicon 2012,59(4),516-523","journal-title":"Toxicon"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0021-9258(18)54042-4","volume":"268","author":"Scarborough R.M.","year":"1993","unstructured":"Scarborough R.M.; Naughton M.A.; Teng W.; Rose J.W.; Phillips D.R.; Nannizzi L.; Arfsten A.; Campbell A.M.; Charo I.F.; Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993,268(2),1066-1073","journal-title":"J Biol Chem"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1042\/BIO04106010","volume":"41","author":"Koh C.Y.","year":"2019","unstructured":"Koh C.Y.; Kini R.M.; Biochemists\u2019 bliss: harnessing the power of snake toxins to treat cardiovascular diseases. Biochemist (Lond) 2019,41,10-14","journal-title":"Biochemist (Lond)"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1007\/s11239-016-1343-6","volume":"42","author":"Nielsen V.G.","year":"2016","unstructured":"Nielsen V.G.; Ancrod revisited: viscoelastic analyses of the effects of Calloselasma rhodostoma venom on plasma coagulation and fibrinolysis. J Thromb Thrombolysis 2016,42(2),288-293","journal-title":"J Thromb Thrombolysis"},{"key":"ref=70","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018534","volume":"98","author":"Yao Y-T.","year":"2019","unstructured":"Yao Y-T.; Yuan X.; Fang N.X.; Hemocoagulase reduces postoperative bleeding and blood transfusion in cardiac surgical patients: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 2019,98(52)","journal-title":"Medicine (Baltimore)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3181\/00379727-161-40584","volume":"161","author":"De Bold A.J.","year":"1979","unstructured":"De Bold A.J.; Heart atria granularity effects of changes in water-electrolyte balance. Proc Soc Exp Biol Med 1979,161(4),508-511","journal-title":"Proc Soc Exp Biol Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/0024-3205(81)90370-2","volume":"28","author":"de Bold A.J.","year":"1981","unstructured":"de Bold A.J.; Borenstein H.B.; Veress A.T.; Sonnenberg H.; A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 1981,28(1),89-94","journal-title":"Life Sci"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0006-291X(84)91077-5","volume":"118","author":"Kangawa K.","year":"1984","unstructured":"Kangawa K.; Matsuo H.; Purification and complete amino acid sequence of \u03b1-human atrial natriuretic polypeptide (\u03b1-hANP). Biochem Biophys Res Commun 1984,118(1),131-139","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jvc.2009.01.001","volume":"11","author":"van Kimmenade R.R.J.","year":"2009","unstructured":"van Kimmenade R.R.J.; Januzzi J.L.; The evolution of the natriuretic peptides - Current applications in human and animal medicine. J Vet Cardiol 2009,11(Suppl. 1),S9-S21","journal-title":"J Vet Cardiol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S2213-8587(16)30196-6","volume":"4","author":"Willeit P.","year":"2016","unstructured":"Willeit P.; Kaptoge S.; Welsh P.; Butterworth A.S.; Chowdhury R.; Spackman S.A.; Pennells L.; Gao P.; Burgess S.; Freitag D.F.; Sweeting M.; Wood A.M.; Cook N.R.; Judd S.; Trompet S.; Nambi V.; Olsen M.H.; Everett B.M.; Kee F.; \u00c4rnl\u00f6v J.; Salomaa V.; Levy D.; Kauhanen J.; Laukkanen J.A.; Kavousi M.; Ninomiya T.; Casas J.P.; Daniels L.B.; Lind L.; Kistorp C.N.; Rosenberg J.; Mueller T.; Rubattu S.; Panagiotakos D.B.; Franco O.H.; de Lemos J.A.; Luchner A.; Kizer J.R.; Kiechl S.; Salonen J.T.; Goya Wannamethee S.; de Boer R.A.; Nordestgaard B.G.; Andersson J.; J\u00f8rgensen T.; Melander O.; Ballantyne, ChM.; DeFilippi, Ch.; Ridker, P.M.; Cushman, M.; Rosamond, W.D.; Thompson, S.G.; Gudnason, V.; Sattar, N.; Danesh, J.; Di Angelantonio, E. Natriuretic Peptides Studies Collaboration. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endocrinol 2016,4(10),840-849","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1056\/NEJMcibr1204796","volume":"367","author":"Wang T.J.","year":"2012","unstructured":"Wang T.J.; The natriuretic peptides and fat metabolism. N Engl J Med 2012,367(4),377-378","journal-title":"N Engl J Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJM199807303390507","volume":"339","author":"Levin E.R.","year":"1998","unstructured":"Levin E.R.; Gardner D.G.; Samson W.K.; Natriuretic peptides. N Engl J Med 1998,339(5),321-328","journal-title":"N Engl J Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","volume":"35","author":"Volpe M.","year":"2014","unstructured":"Volpe M.; Rubattu S.; Burnett J.; Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 2014,35(7),419-425","journal-title":"Eur Heart J"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s10741-007-9016-3","volume":"12","author":"Lee C.Y.","year":"2007","unstructured":"Lee C.Y.; Burnett J.C.; Natriuretic peptides and therapeutic applications. Heart Fail Rev 2007,12(2),131-142","journal-title":"Heart Fail Rev"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/B978-0-12-801028-0.00186-0","author":"Tsukada T.","year":"2016","unstructured":"Tsukada T.;  Handbook of hormones 2016,289-281","journal-title":"Handbook of hormones"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.yfrne.2007.05.001","volume":"28","author":"Takei Y.","year":"2007","unstructured":"Takei Y.; Ogoshi M.; Inoue K.A.; \u2018reverse\u2019 phylogenetic approach for identification of novel osmoregulatory and cardiovascular hormones in vertebrates. Front Neuroendocrinol 2007,28(4),143-160","journal-title":"Front Neuroendocrinol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/978-3-540-68964-5_15","volume":"191","author":"Potter L.R.","year":"2009","unstructured":"Potter L.R.; Yoder A.R.; Flora D.R.; Antos L.K.; Dickey D.M.; Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol 2009,191,341-366","journal-title":"Handb Exp Pharmacol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1210\/er.2005-0014","volume":"27","author":"Potter L.R.","year":"2006","unstructured":"Potter L.R.; Abbey-Hosch S.; Dickey D.M.; Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev 2006,27(1),47-72","journal-title":"Endocr Rev"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/378065a0","volume":"378","author":"Lopez M.J.","year":"1995","unstructured":"Lopez M.J.; Wong S.K.; Kishimoto I.; Dubois S.; Mach V.; Friesen J.; Garbers D.L.; Beuve A.; Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995,378(6552),65-68","journal-title":"Nature"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.RES.0000232322.06633.d3","volume":"99","author":"Singh G.","year":"2006","unstructured":"Singh G.; Kuc R.E.; Maguire J.J.; Fidock M.; Davenport A.P.; Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ Res 2006,99(2),183-190","journal-title":"Circ Res"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cbd.2005.10.002","volume":"1","author":"Inoue K.","year":"2006","unstructured":"Inoue K.; Takei Y.; Molecular evolution of the natriuretic peptide system as revealed by comparative genomics. Comp Biochem Physiol Part D Genomics Proteomics 2006,1(1),69-76","journal-title":"Comp Biochem Physiol Part D Genomics Proteomics"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"R940","DOI":"10.1152\/ajpregu.00389.2001","volume":"282","author":"Takei Y.","year":"2002","unstructured":"Takei Y.; Hirose S.; The natriuretic peptide system in eels: a key endocrine system for euryhalinity? Am J Physiol Regul Integr Comp Physiol 2002,282(4),R940-R951","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=88","first-page":"H1618","volume":"277","author":"Wennberg P.W.","year":"1999","unstructured":"Wennberg P.W.; Miller V.M.; Rabelink T.; Burnett J.C.; Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. Am J Physiol 1999,277(4),H1618-H1621","journal-title":"Am J Physiol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.regpep.2003.12.011","volume":"118","author":"Piao F.L.","year":"2004","unstructured":"Piao F.L.; Park S.H.; Han J.H.; Cao C.; Kim S.Z.; Kim S.H.; Dendroaspis natriuretic peptide and its functions in pig ovarian granulosa cells. Regul Pept 2004,118(3),193-198","journal-title":"Regul Pept"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"10278","DOI":"10.1073\/pnas.96.18.10278","volume":"96","author":"Jaubert J.","year":"1999","unstructured":"Jaubert J.; Jaubert F.; Martin N.; Washburn L.L.; Lee B.K.; Eicher E.M.; Gu\u00e9net J.L.; Three new allelic mouse mutations that cause skeletal overgrowth involve the natriuretic peptide receptor C gene (Npr3). Proc Natl Acad Sci USA 1999,96(18),10278-10283","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"7403","DOI":"10.1073\/pnas.96.13.7403","volume":"96","author":"Matsukawa N.","year":"1999","unstructured":"Matsukawa N.; Grzesik W.J.; Takahashi N.; Pandey K.N.; Pang S.; Yamauchi M.; Smithies O.; The natriuretic peptide clearance receptor locally modulates the physiological effects of the natriuretic peptide system. Proc Natl Acad Sci USA 1999,96(13),7403-7408","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1113\/jphysiol.2007.144253","volume":"586","author":"Rose R.A.","year":"2008","unstructured":"Rose R.A.; Giles W.R.; Natriuretic peptide C receptor signalling in the heart and vasculature. J Physiol 2008,586(2),353-366","journal-title":"J Physiol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.bbrc.2007.04.079","volume":"358","author":"Johns D.G.","year":"2007","unstructured":"Johns D.G.; Ao Z.; Heidrich B.J.; Hunsberger G.E.; Graham T.; Payne L.; Elshourbagy N.; Lu Q.; Aiyar N.; Douglas S.A.; Dendroaspis natriuretic peptide binds to the natriuretic peptide clearance receptor. Biochem Biophys Res Commun 2007,358(1),145-149","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1432-1033.1995.102_1.x","volume":"233","author":"Kashiwagi M.","year":"1995","unstructured":"Kashiwagi M.; Katafuchi T.; Kato A.; Inuyama H.; Ito T.; Hagiwara H.; Takei Y.; Hirose S.; Cloning and properties of a novel natriuretic peptide receptor, NPR-D. Eur J Biochem 1995,233(1),102-109","journal-title":"Eur J Biochem"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1242\/jeb.027391","volume":"213","author":"Tota B.","year":"2010","unstructured":"Tota B.; Cerra M.C.; Gattuso A.; Catecholamines, cardiac natriuretic peptides and chromogranin A: evolution and physiopathology of a \u2018whip-brake\u2019 system of the endocrine heart. J Exp Biol 2010,213(Pt 18),3081-3103","journal-title":"J Exp Biol"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.tem.2006.06.006","volume":"17","author":"Garbers D.L.","year":"2006","unstructured":"Garbers D.L.; Chrisman T.D.; Wiegn P.; Katafuchi T.; Albanesi J.P.; Bielinski V.; Barylko B.; Redfield M.M.; Burnett J.C.; Membrane guanylyl cyclase receptors: an update. Trends Endocrinol Metab 2006,17(6),251-258","journal-title":"Trends Endocrinol Metab"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"18500","DOI":"10.1073\/pnas.1103300108","volume":"108","author":"Klaiber M.","year":"2011","unstructured":"Klaiber M.; Dankworth B.; Kruse M.; Hartmann M.; Nikolaev V.O.; Yang R.B.; V\u00f6lker K.; Gassner B.; Oberwinkler H.; Feil R.; Freichel M.; Groschner K.; Skryabin B.V.; Frantz S.; Birnbaumer L.; Pongs O.; Kuhn M.; A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptide. Proc Natl Acad Sci USA 2011,108(45),18500-18505","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1126\/science.2935937","volume":"231","author":"Burnett J.C.","year":"1986","unstructured":"Burnett J.C.; Kao P.C.; Hu D.C.; Heser D.W.; Heublein D.; Granger J.P.; Opgenorth T.J.; Reeder G.S.; Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986,231(4742),1145-1147","journal-title":"Science"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1172\/JCI112723","volume":"78","author":"Cody R.J.","year":"1986","unstructured":"Cody R.J.; Atlas S.A.; Laragh J.H.; Kubo S.H.; Covit A.B.; Ryman K.S.; Shaknovich A.; Pondolfino K.; Clark M.; Camargo M.J.; Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest 1986,78(5),1362-1374","journal-title":"J Clin Invest"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0196-9781(89)90131-9","volume":"10","author":"Yandle T.G.","year":"1989","unstructured":"Yandle T.G.; Brennan S.O.; Espiner E.A.; Nicholls M.G.; Richards A.M.; Endopeptidase-24.11 in human plasma degrades atrial natriuretic factor (ANF) to ANF(99-105\/106-126). Peptides 1989,10(4),891-894","journal-title":"Peptides"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1253\/circj.69.283","volume":"69","author":"Suwa M.","year":"2005","unstructured":"Suwa M.; Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the \u2018real world\u2019 of therapy. Circ J 2005,69,283-290","journal-title":"Circ J"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1253\/circj.CJ-07-0760","volume":"72","author":"Nomura F.","year":"2008","unstructured":"Nomura F.; Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide effects observed through monitoring dyspnea in acute decompensated heart failure study. Circ J 2008,72,1777-1786","journal-title":"Circ J"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/332078a0","volume":"332","author":"Sudoh T.","year":"1988","unstructured":"Sudoh T.; Kangawa K.; Minamino N.; Matsuo H.; A new natriuretic peptide in porcine brain. Nature 1988,332(6159),78-81","journal-title":"Nature"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1161\/01.CIR.87.2.464","volume":"87","author":"Yoshimura M.","year":"1993","unstructured":"Yoshimura M.; Yasue H.; Okumura K.; Ogawa H.; Jougasaki M.; Mukoyama M.; Nakao K.; Imura H.; Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993,87(2),464-469","journal-title":"Circulation"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrcardio.2009.197","volume":"7","author":"O\u2019Donoghue M.","year":"2010","unstructured":"O\u2019Donoghue M.; Braunwald E.; Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 2010,7(1),13-20","journal-title":"Nat Rev Cardiol"},{"key":"ref=106","first-page":"e99","volume":"116","author":"Tang W.H.","year":"2007","unstructured":"Tang W.H.; Francis G.S.; Morrow D.A.; Newby L.K.; Cannon C.P.; Jesse R.L.; Storrow A.B.; Christenson R.H.; Apple F.S.; Ravkilde J.; Wu A.H.; National academy of clinical biochemistry laboratory medicine. National academy of clinical biochemistry laboratory medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007,116(5),e99-e109","journal-title":"Circulation"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1186\/cc9398","volume":"15","author":"Noveanu M.","year":"2011","unstructured":"Noveanu M.; Breidthardt T.; Potocki M.; Reichlin T.; Twerenbold R.; Uthoff H.; Socrates T.; Arenja N.; Reiter M.; Meissner J.; Heinisch C.; Stalder S.; Mueller C.; Direct comparison of serial B-type natriuretic peptide and NT-proBNP levels for prediction of short- and long-term outcome in acute decompensated heart failure. Crit Care 2011,15(1),R1","journal-title":"Crit Care"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.36.3.355","volume":"36","author":"Pemberton C.J.","year":"2000","unstructured":"Pemberton C.J.;  Deconvolution analysis of cardiac natriuretic peptides during acute volume overload  Hypertension (Dallas, Tex :1979), 2000,36,355-359","journal-title":"Deconvolution analysis of cardiac natriuretic peptides during acute volume overload  Hypertension (Dallas, Tex :1979),"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cca.2007.02.031","volume":"380","author":"Kroll M.H.","year":"2007","unstructured":"Kroll M.H.; Using the single-compartment ratio model to calculate half-life, NT-proBNP as an example. Clin Chim Acta 2007,380,197-202","journal-title":"Clin Chim Acta"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1056\/NEJM200007273430403","volume":"343","author":"Colucci W.S.","year":"2000","unstructured":"Colucci W.S.; Elkayam U.; Horton D.P.; Abraham W.T.; Bourge R.C.; Johnson A.D.; Wagoner L.E.; Givertz M.M.; Liang C.S.; Neibaur M.; Haught W.H.; LeJemtel T.H.; Nesiritide Study Group. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000,343(4),246-253","journal-title":"N Engl J Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ahj.2015.04.006","volume":"170","author":"Khazanie P.","year":"2015","unstructured":"Khazanie P.; Heizer G.M.; Hasselblad V.; Armstrong P.W.; Califf R.M.; Ezekowitz J.; Dickstein K.; Levy W.C.; McMurray J.J.; Metra M.; Tang W.H.; Teerlink J.R.; Voors A.A.; O\u2019Connor C.M.; Hernandez A.F.; Starling R.; Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. Am Heart J 2015,170(2),290-297","journal-title":"Am Heart J"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1517\/17425250903042300","volume":"5","author":"Tong A.T.","year":"2009","unstructured":"Tong A.T.; Rozner M.A.; The role of nesiritide in heart failure. Expert Opin Drug Metab Toxicol 2009,5(7),823-834","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2147\/TCRM.S143247","volume":"14","author":"Hua P.","year":"2018","unstructured":"Hua P.; Liu J.; Tao J.; Lin X.; Zou R.; Zhang D.; Yang S.; Safety and efficacy of the perioperative administration of recombinant human brain natriuretic peptide (rhBNP): a systematic review and meta-analysis. Ther Clin Risk Manag 2018,14,313-321","journal-title":"Ther Clin Risk Manag"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"17","DOI":"10.22514\/SV62.102011.2","volume":"6","author":"Maj G.","year":"2011","unstructured":"Maj G.; Nesiritide and clinically relevant outcomes in cardiac surgery: a meta-analysis of randomized studies. Signa Vitae 2011,6,17-23","journal-title":"Signa Vitae"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/0006-291X(90)92401-K","volume":"168","author":"Sudoh T.","year":"1990","unstructured":"Sudoh T.; Minamino N.; Kangawa K.; Matsuo H.; C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990,168(2),863-870","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1073\/pnas.0336365100","volume":"100","author":"Chauhan S.D.","year":"2003","unstructured":"Chauhan S.D.; Nilsson H.; Ahluwalia A.; Hobbs A.J.; Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor. Proc Natl Acad Sci USA 2003,100(3),1426-1431","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"25847","DOI":"10.1074\/jbc.M301223200","volume":"278","author":"Wu C.","year":"2003","unstructured":"Wu C.; Wu F.; Pan J.; Morser J.; Wu Q.; Furin-mediated processing of Pro-C-type natriuretic peptide. J Biol Chem 2003,278(28),25847-25852","journal-title":"J Biol Chem"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1210\/endo.130.1.1309330","volume":"130","author":"Suga S.","year":"1992","unstructured":"Suga S.; Nakao K.; Hosoda K.; Mukoyama M.; Ogawa Y.; Shirakami G.; Arai H.; Saito Y.; Kambayashi Y.; Inouye K.; Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992,130(1),229-239","journal-title":"Endocrinology"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1172\/JCI94912","volume":"127","author":"Kanai Y.","year":"2017","unstructured":"Kanai Y.; Yasoda A.; Mori K.P.; Watanabe-Takano H.; Nagai-Okatani C.; Yamashita Y.; Hirota K.; Ueda Y.; Yamauchi I.; Kondo E.; Yamanaka S.; Sakane Y.; Nakao K.; Fujii T.; Yokoi H.; Minamino N.; Mukoyama M.; Mochizuki N.; Inagaki N.; Circulating osteocrin stimulates bone growth by limiting C-type natriuretic peptide clearance. J Clin Invest 2017,127(11),4136-4147","journal-title":"J Clin Invest"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/eurheartj\/ehz093","volume":"41","author":"Moyes A.J.","year":"2020","unstructured":"Moyes A.J.; C-type natriuretic peptide co-ordinates cardiac structure and function. Eur Heart J 2020,41(9),1006-1020","journal-title":"Eur Heart J"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.ejheart.2004.12.009","volume":"7","author":"Del Ry S.","year":"2005","unstructured":"Del Ry S.; Passino C.; Maltinti M.; Emdin M.; Giannessi D.; C-type natriuretic peptide plasma levels increase in patients with chronic heart failure as a function of clinical severity. Eur J Heart Fail 2005,7(7),1145-1148","journal-title":"Eur J Heart Fail"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.3390\/ijms20092281","volume":"20","author":"Moyes A.J.","year":"2019","unstructured":"Moyes A.J.; Hobbs A.J.; C-type natriuretic peptide: a multifaceted paracrine regulator in the heart and vasculature. Int J Mol Sci 2019,20(9),2281","journal-title":"Int J Mol Sci"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1161\/CIRCULATIONAHA.118.036344","volume":"139","author":"Bubb K.J.","year":"2019","unstructured":"Bubb K.J.; Aubdool A.A.; Moyes A.J.; Lewis S.; Drayton J.P.; Tang O.; Mehta V.; Zachary I.C.; Abraham D.J.; Tsui J.; Hobbs A.J.; Endothelial C-type natriuretic peptide Is a critical regulator of angiogenesis and vascular remodeling. Circulation 2019,139(13),1612-1628","journal-title":"Circulation"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1161\/CIRCULATIONAHA.106.685743","volume":"116","author":"Peltonen T.O.","year":"2007","unstructured":"Peltonen T.O.; Taskinen P.; Soini Y.; Rys\u00e4 J.; Ronkainen J.; Ohtonen P.; Satta J.; Juvonen T.; Ruskoaho H.; Leskinen H.; Distinct downregulation of C-type natriuretic peptide system in human aortic valve stenosis. Circulation 2007,116(11),1283-1289","journal-title":"Circulation"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1177\/002215540205000606","volume":"50","author":"Casco V.H.","year":"2002","unstructured":"Casco V.H.; Veinot J.P.; Kuroski de Bold M.L.; Masters R.G.; Stevenson M.M.; de Bold A.J.; Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002,50(6),799-809","journal-title":"J Histochem Cytochem"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ejvs.2012.02.010","volume":"43","author":"Kuehnl A.","year":"2012","unstructured":"Kuehnl A.; Pelisek J.; Pongratz J.; Eckstein H.H.; C-type natriuretic peptide and its receptors in atherosclerotic plaques of the carotid artery of clinically asymptomatic patients. Eur J Vasc Endovasc Surg 2012,43(6),649-654","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1097\/00005344-199609000-00008","volume":"28","author":"Seymour A.A.","year":"1996","unstructured":"Seymour A.A.; Mathers P.D.; Abboa-Offei B.E.; Asaad M.M.; Weber H.; Renal and depressor activity of C-natriuretic peptide in conscious monkeys: effects of enzyme inhibitors. J Cardiovasc Pharmacol 1996,28(3),397-401","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1161\/CIRCULATIONAHA.117.033383","volume":"138","author":"\u0160piranec K.","year":"2018","unstructured":"\u0160piranec K.; Chen W.; Werner F.; Nikolaev V.O.; Naruke T.; Koch F.; Werner A.; Eder-Negrin P.; Di\u00e9guez-Hurtado R.; Adams R.H.; Baba H.A.; Schmidt H.; Schuh K.; Skryabin B.V.; Movahedi K.; Schweda F.; Kuhn M.; Endothelial C-type natriuretic peptide acts on pericytes to regulate microcirculatory flow and blood pressure. Circulation 2018,138(5),494-508","journal-title":"Circulation"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.2174\/138161210794519237","volume":"16","author":"Lumsden N.G.","year":"2010","unstructured":"Lumsden N.G.; Khambata R.S.; Hobbs A.J.; C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Curr Pharm Des 2010,16(37),4080-4088","journal-title":"Curr Pharm Des"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1161\/01.CIR.0000141802.29945.34","volume":"110","author":"Hobbs A.","year":"2004","unstructured":"Hobbs A.; Foster P.; Prescott C.; Scotland R.; Ahluwalia A.; Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia\/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide. Circulation 2004,110(10),1231-1235","journal-title":"Circulation"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ejheart.2007.02.006","volume":"9","author":"Wang Y.","year":"2007","unstructured":"Wang Y.; de Waard M.C.; Sterner-Kock A.; Stepan H.; Schultheiss H.P.; Duncker D.J.; Walther T.; Cardiomyocyte-restricted over-expression of C-type natriuretic peptide prevents cardiac hypertrophy induced by myocardial infarction in mice. Eur J Heart Fail 2007,9(6-7),548-557","journal-title":"Eur J Heart Fail"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"13928","DOI":"10.1016\/S0021-9258(19)49658-0","volume":"267","author":"Schweitz H.","year":"1992","unstructured":"Schweitz H.; Vigne P.; Moinier D.; Frelin C.; Lazdunski M.; A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps). J Biol Chem 1992,267(20),13928-13932","journal-title":"J Biol Chem"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1046\/j.1523-1755.1999.00573.x","volume":"56","author":"Lisy O.","year":"1999","unstructured":"Lisy O.; Jougasaki M.; Heublein D.M.; Schirger J.A.; Chen H.H.; Wennberg P.W.; Burnett J.C.; Renal actions of synthetic dendroaspis natriuretic peptide. Kidney Int 1999,56(2),502-508","journal-title":"Kidney Int"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/01.HYP.37.4.1089","volume":"37","author":"Lisy O.","year":"2001","unstructured":"Lisy O.;  Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure  Hypertension (Dallas, Tex : 1979), 2001,37,1089-1094","journal-title":"Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure  Hypertension (Dallas, Tex : 1979),"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3858\/emm.2012.44.6.041","volume":"44","author":"Park S-A.","year":"2012","unstructured":"Park S-A.; Kim T.G.; Han M.K.; Ha K.C.; Kim S.Z.; Kwak Y.G.; Dendroaspis natriuretic peptide regulates the cardiac L-type Ca2+ channel activity by the phosphorylation of \u03b11c proteins. Exp Mol Med 2012,44(6),363-368","journal-title":"Exp Mol Med"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/S0735-1097(02)02127-7","volume":"40","author":"Chen H.H.","year":"2002","unstructured":"Chen H.H.; Lainchbury J.G.; Burnett J.C.; Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. J Am Coll Cardiol 2002,40(6),1186-1191","journal-title":"J Am Coll Cardiol"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1242\/jeb.00883","volume":"207","author":"Jennings B.L.","year":"2004","unstructured":"Jennings B.L.; Broughton B.R.; Donald J.A.; Nitric oxide control of the dorsal aorta and the intestinal vein of the Australian short-finned eel Anguilla australis. J Exp Biol 2004,207(Pt 8),1295-1303","journal-title":"J Exp Biol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"R1549","DOI":"10.1152\/ajpregu.00789.2009","volume":"298","author":"Nobata S.","year":"2010","unstructured":"Nobata S.; Ventura A.; Kaiya H.; Takei Y.; Diversified cardiovascular actions of six homologous natriuretic peptides (ANP, BNP, VNP, CNP1, CNP3, and CNP4) in conscious eels. Am J Physiol Regul Integr Comp Physiol 2010,298(6),R1549-R1559","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/S1095-6433(99)00178-6","volume":"125","author":"Loretz C.A.","year":"2000","unstructured":"Loretz C.A.; Pollina C.; Natriuretic peptides in fish physiology. Comp Biochem Physiol A Mol Integr Physiol 2000,125(2),169-187","journal-title":"Comp Biochem Physiol A Mol Integr Physiol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1677\/joe.0.1490441","volume":"149","author":"Kaiya H.","year":"1996","unstructured":"Kaiya H.; Takei Y.; Osmotic and volaemic regulation of atrial and ventricular natriuretic peptide secretion in conscious eels. J Endocrinol 1996,149(3),441-447","journal-title":"J Endocrinol"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2108\/zsj.18.1253","volume":"18","author":"Tsukada T.","year":"2001","unstructured":"Tsukada T.; Takei Y.; Relative potency of three homologous natriuretic peptides (ANP, CNP and VNP) in Eel Osmoregulation. Zool Sci 2001,18,1253-1258","journal-title":"Zool Sci"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0008-6363(01)00331-5","volume":"51","author":"Forssmann W.","year":"2001","unstructured":"Forssmann W.; Meyer M.; Forssmann K.; The renal urodilatin system: clinical implications. Cardiovasc Res 2001,51(3),450-462","journal-title":"Cardiovasc Res"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0008-6363(99)00371-5","volume":"45","author":"Inserte J.","year":"2000","unstructured":"Inserte J.; Garcia-Dorado D.; Agull\u00f3 L.; Paniagua A.; Soler-Soler J.; Urodilatin limits acute reperfusion injury in the isolated rat heart. Cardiovasc Res 2000,45(2),351-359","journal-title":"Cardiovasc Res"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0008-6363(01)00242-5","volume":"51","author":"Padilla F.","year":"2001","unstructured":"Padilla F.; Garcia-Dorado D.; Agull\u00f3 L.; Barrab\u00e9s J.A.; Inserte J.; Escalona N.; Meyer M.; Mirabet M.; Pina P.; Soler-Soler J.; Intravenous administration of the natriuretic peptide urodilatin at low doses during coronary reperfusion limits infarct size in anesthetized pigs. Cardiovasc Res 2001,51(3),592-600","journal-title":"Cardiovasc Res"},{"key":"ref=145","first-page":"935","volume":"38","author":"Hausenloy D.J.","year":"2017","unstructured":"Hausenloy D.J.; Botker H.E.; Engstrom T.; Erlinge D.; Heusch G.; Ibanez B.; Kloner R.A.; Ovize M.; Yellon D.M.; Garcia-Dorado D.; Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J 2017,38(13),935-941","journal-title":"Eur Heart J"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"C1260","DOI":"10.1152\/ajpcell.00033.2012","volume":"303","author":"Dobrivojevi\u0107 M.","year":"2012","unstructured":"Dobrivojevi\u0107 M.; Sin\u0111i\u0107 A.; Edemir B.; Kalweit S.; Forssmann W.G.; Hirsch J.R.; Interaction between bradykinin and natriuretic peptides via RGS protein activation in HEK-293 cells. Am J Physiol Cell Physiol 2012,303(12),C1260-C1268","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.expneurol.2016.07.007","volume":"284","author":"Dobrivojevi\u0107 M.","year":"2016","unstructured":"Dobrivojevi\u0107 M.; \u0160piranec K.; Gorup D.; Erjavec I.; Habek N.; Radmilovi\u0107 M.; Unfirer S.; \u0106osi\u0107 A.; Drenjan\u010devi\u0107 I.; Gajovi\u0107 S.; Sin\u0111i\u0107 A.;  Urodilatin reverses the detrimental influence of bradykinin in acute ischemic stroke  Exp Neurol 2016,284(Pt A),1-10","journal-title":"Urodilatin reverses the detrimental influence of bradykinin in acute ischemic stroke  Exp Neurol"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"R684","DOI":"10.1152\/ajpcell.1999.276.3.C684","volume":"276","author":"Bestle M.H.","year":"1999","unstructured":"Bestle M.H.; Olsen N.V.; Christensen P.; Jensen B.V.; Bie P.; Cardiovascular, endocrine, and renal effects of urodilatin in normal humans. Am J Physiol 1999,276(3),R684-R695","journal-title":"Am J Physiol"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2147\/TCRM.S179302","volume":"15","author":"Machaj F.","year":"2019","unstructured":"Machaj F.; Dembowska E.; Rosik J.; Szostak B.; Mazurek-Mochol M.; Pawlik A.; New therapies for the treatment of heart failure: a summary of recent accomplishments. Ther Clin Risk Manag 2019,15,147-155","journal-title":"Ther Clin Risk Manag"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40138-018-0150-0","volume":"6","author":"Shah T.","year":"2018","unstructured":"Shah T.; Ularitide in acute heart failure. Curr Emerg Hosp Med Rep 2018,6,17-23","journal-title":"Curr Emerg Hosp Med Rep"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJMoa1601895","volume":"376","author":"Packer M.","year":"2017","unstructured":"Packer M.; O\u2019Connor C.; McMurray J.J.V.; Wittes J.; Abraham W.T.; Anker S.D.; Dickstein K.; Filippatos G.; Holcomb R.; Krum H.; Maggioni A.P.; Mebazaa A.; Peacock W.F.; Petrie M.C.; Ponikowski P.; Ruschitzka F.; van Veldhuisen D.J.; Kowarski L.S.; Schactman M.; Holzmeister J.;  TRUE-AHF Investigators Effect of ularitide on cardiovascular mortality in acute heart failure. N Engl J Med 2017,376(20),1956-1964","journal-title":"N Engl J Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/0014-5793(96)00774-0","volume":"392","author":"Barbouche R.","year":"1996","unstructured":"Barbouche R.; Marrakchi N.; Mansuelle P.; Krifi M.; Fenouillet E.; Rochat H.; el Ayeb M.; Novel anti-platelet aggregation polypeptides from Vipera lebetina venom: isolation and characterization. FEBS Lett 1996,392(1),6-10","journal-title":"FEBS Lett"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1016\/S0041-0101(98)00118-4","volume":"36","author":"Barbouche R.","year":"1998","unstructured":"Barbouche R.; Marrakchi N.; Mabrouk K.; Krifi M.N.; Van Rietschoten J.; Fenouillet E.; El Ayeb M.; Rochat H.; Anti-platelet activity of the peptides composing the lebetin 1 family, a new class of inhibitors of platelet aggregation. Toxicon 1998,36(12),1939-1947","journal-title":"Toxicon"},{"key":"ref=154","first-page":"207","volume":"31","author":"Marrakchi N.","year":"2001","unstructured":"Marrakchi N.; Mabrouk K.; Regaya I.; Sarray S.; Fathallah M.; Rochat H.; El Ayeb M.; Lebetin peptides: potent platelet aggregation inhibitors. Haemostasis 2001,31(3-6),207-210","journal-title":"Haemostasis"},{"key":"ref=155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162632","volume":"11","author":"Tourki B.","year":"2016","unstructured":"Tourki B.; Mat\u00e9o P.; Morand J.; Elayeb M.; Godin-Ribuot D.; Marrakchi N.; Belaidi E.; Messadi E.; Lebetin 2, a snake venom-derived natriuretic peptide, attenuates acute myocardial ischemic injury through the modulation of mitochondrial permeability transition pore at the time of reperfusion. PLoS One 2016,11(9)","journal-title":"PLoS One"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0014-5793(03)01455-8","volume":"557","author":"Amininasab M.","year":"2004","unstructured":"Amininasab M.; Elmi M.M.; Endlich N.; Endlich K.; Parekh N.; Naderi-Manesh H.; Schaller J.; Mostafavi H.; Sattler M.; Sarbolouki M.N.; Muhle-Goll C.; Functional and structural characterization of a novel member of the natriuretic family of peptides from the venom of Pseudocerastes persicus. FEBS Lett 2004,557(1-3),104-108","journal-title":"FEBS Lett"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"B25","DOI":"10.1093\/eurheartj\/sui010","volume":"7","author":"Burnett J.C.","year":"2005","unstructured":"Burnett J.C.; Nesiritide: new hope for acute heart failure syndromes? Eur Heart J Suppl 2005,7,B25-B30","journal-title":"Eur Heart J Suppl"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.jacbts.2016.10.001","volume":"1","author":"Meems L.M.G.","year":"2016","unstructured":"Meems L.M.G.; Burnett J.C.; Jr Innovative therapeutics: designer natriuretic peptides. JACC Basic Transl Sci 2016,1(7),557-567","journal-title":"JACC Basic Transl Sci"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.3390\/ijms20112629","volume":"20","author":"Tanase D.M.","year":"2019","unstructured":"Tanase D.M.; Radu S.; Al Shurbaji S.; Baroi G.L.; Florida Costea C.; Turliuc M.D.; Ouatu A.; Floria M.; Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications. Int J Mol Sci 2019,20(11),2629","journal-title":"Int J Mol Sci"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1042\/CS20150469","volume":"130","author":"Volpe M.","year":"2016","unstructured":"Volpe M.; Carnovali M.; Mastromarino V.; The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment. Clin Sci (Lond) 2016,130(2),57-77","journal-title":"Clin Sci (Lond)"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.bbrc.2014.03.110","volume":"446","author":"Jiang Y.S.","year":"2014","unstructured":"Jiang Y.S.; Lei J.Y.; Chen Y.; Jin J.; Vasonatrin peptide stimulates both of the natriuretic peptide receptors, NPRA and NPRB. Biochem Biophys Res Commun 2014,446(4),1276-1280","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"H71","DOI":"10.1152\/ajpcell.1993.264.1.C71","volume":"264","author":"Wei C.M.","year":"1993","unstructured":"Wei C.M.; Aarhus L.L.; Miller V.M.; Burnett J.C.; Jr Action of C-type natriuretic peptide in isolated canine arteries and veins. Am J Physiol 1993,264(1 Pt 2),H71-H73","journal-title":"Am J Physiol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1172\/JCI116800","volume":"92","author":"Wei C.M.","year":"1993","unstructured":"Wei C.M.; Kim C.H.; Miller V.M.; Burnett J.C.; Jr Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. J Clin Invest 1993,92(4),2048-2052","journal-title":"J Clin Invest"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"H281","DOI":"10.1152\/ajpheart.00666.2014","volume":"308","author":"Shi Z.","year":"2015","unstructured":"Shi Z.; Fu F.; Yu L.; Xing W.; Su F.; Liang X.; Tie R.; Ji L.; Zhu M.; Yu J.; Zhang H.; Vasonatrin peptide attenuates myocardial ischemia-reperfusion injury in diabetic rats and underlying mechanisms. Am J Physiol Heart Circ Physiol 2015,308(4),H281-H290","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jacc.2008.02.077","volume":"52","author":"Lisy O.","year":"2008","unstructured":"Lisy O.; Huntley B.K.; McCormick D.J.; Kurlansky P.A.; Burnett J.C.; Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. J Am Coll Cardiol 2008,52(1),60-68","journal-title":"J Am Coll Cardiol"},{"key":"ref=166","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052422","volume":"7","author":"Martin F.L.","year":"2012","unstructured":"Martin F.L.; Sangaralingham S.J.; Huntley B.K.; McKie P.M.; Ichiki T.; Chen H.H.; Korinek J.; Harders G.E.; Burnett J.C.; Jr CD-NP; a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart. PLoS One 2012,7(12)","journal-title":"PLoS One"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1016\/j.cardfail.2007.06.307","volume":"13","author":"Lee C.Y.W.","year":"2007","unstructured":"Lee C.Y.W.; Burnett J.C.; Discovery of a novel synthetic natriuretic peptide, CU-NP. J Card Fail 2007,13,S74","journal-title":"J Card Fail"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ijcard.2014.08.032","volume":"176","author":"Volpe M.","year":"2014","unstructured":"Volpe M.; Natriuretic peptides and cardio-renal disease. Int J Cardiol 2014,176(3),630-639","journal-title":"Int J Cardiol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/cvr\/cvq254","volume":"88","author":"Kili\u0107 A.","year":"2010","unstructured":"Kili\u0107 A.; Rajapurohitam V.; Sandberg S.M.; Zeidan A.; Hunter J.C.; Said Faruq N.; Lee C.Y.; Burnett J.C.; Karmazyn M.; A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway. Cardiovasc Res 2010,88(3),434-442","journal-title":"Cardiovasc Res"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"19196","DOI":"10.1074\/jbc.M109.010777","volume":"284","author":"Dickey D.M.","year":"2009","unstructured":"Dickey D.M.; Yoder A.R.; Potter L.R.; A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation. J Biol Chem 2009,284(29),19196-19202","journal-title":"J Biol Chem"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1073\/pnas.85.11.3792","volume":"85","author":"Kamp F.","year":"1988","unstructured":"Kamp F.; Astumian R.D.; Westerhoff H.V.; Coupling of vectorial proton flow to a biochemical reaction by local electric interactions. Proc Natl Acad Sci USA 1988,85(11),3792-3796","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=172","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000206","volume":"3","author":"McKie P.M.","year":"2014","unstructured":"McKie P.M.; Cataliotti A.; Ichiki T.; Sangaralingham S.J.; Chen H.H.; Burnett J.C.; M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics. J Am Heart Assoc 2014,3(1)","journal-title":"J Am Heart Assoc"},{"key":"ref=173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2016.03.051","volume":"10","author":"Chen H.H.","year":"2016","unstructured":"Chen H.H.; A first-in-human trial of a novel designer natriuretic peptide ZD100 in human hypertension. J Am Soc Hypertens 2016,10","journal-title":"J Am Soc Hypertens"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13036-017-0093-0","volume":"12","author":"Fu S.","year":"2018","unstructured":"Fu S.; Ping P.; Wang F.; Luo L.; Synthesis, secretion, function, metabolism and application of natriuretic peptides in heart failure. J Biol Eng 2018,12,2","journal-title":"J Biol Eng"}],"container-title":["Current Topics in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/186837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/186837\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/186837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T05:22:32Z","timestamp":1627795352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/186837\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":174,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2020,12,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568026620666201013154326","relation":{},"ISSN":["1568-0266"],"issn-type":[{"value":"1568-0266","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-09-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}